Purple Biotech (NASDAQ:PPBT) — Market Cap & Net Worth
Market Cap & Net Worth: Purple Biotech (PPBT)
Purple Biotech (NASDAQ:PPBT) has a market capitalization of $1.64 Million ($1.64 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30156 globally and #6057 in its home market, demonstrating a -41.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Purple Biotech's stock price $1.76 by its total outstanding shares 929456 (929.46K). Review debt load of Purple Biotech to assess the company's total debt and financial obligations.
Purple Biotech Market Cap History: 2015 to 2026
Purple Biotech's market capitalization history from 2015 to 2026. Data shows change from $585.56 Million to $1.64 Million (-42.70% CAGR).
Index Memberships
Purple Biotech is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #894 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2839 of 3165 |
Weight: Purple Biotech's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Purple Biotech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Purple Biotech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
74.05x
Purple Biotech's market cap is 74.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $423.83 Million | $100.00K | -$12.18 Million | 4238.32x | N/A |
| 2018 | $122.69 Million | $1.00 Million | -$5.20 Million | 122.69x | N/A |
| 2019 | $144.92 Million | $1.00 Million | -$5.85 Million | 144.92x | N/A |
| 2020 | $70.82 Million | $1.00 Million | -$28.00 Million | 70.82x | N/A |
| 2021 | $72.31 Million | $-320.00K | -$18.38 Million | -225.97x | N/A |
| 2022 | $25.65 Million | $-910.00K | -$21.67 Million | -28.19x | N/A |
| 2023 | $14.50 Million | $195.80K | -$19.88K | 74.05x | N/A |
Competitor Companies of PPBT by Market Capitalization
Companies near Purple Biotech in the global market cap rankings as of June 18, 2026.
Key companies related to Purple Biotech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Purple Biotech Historical Marketcap From 2015 to 2026
Between 2015 and today, Purple Biotech's market cap moved from $585.56 Million to $ 1.64 Million, with a yearly change of -42.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.64 Million | +167.68% |
| 2025 | $611.12K | -85.98% |
| 2024 | $4.36 Million | -69.94% |
| 2023 | $14.50 Million | -43.48% |
| 2022 | $25.65 Million | -64.52% |
| 2021 | $72.31 Million | +2.10% |
| 2020 | $70.82 Million | -51.13% |
| 2019 | $144.92 Million | +18.12% |
| 2018 | $122.69 Million | -71.05% |
| 2017 | $423.83 Million | -26.69% |
| 2016 | $578.12 Million | -1.27% |
| 2015 | $585.56 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Purple Biotech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.64 Million USD |
| MoneyControl | $1.64 Million USD |
| MarketWatch | $1.64 Million USD |
| marketcap.company | $1.64 Million USD |
| Reuters | $1.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more